Phase III trials of COVID drug Movfor show positive results, says Hetero

The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12-16, 2022, demonstrated that Molnupiravir along with standard of care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Gocu8C1
via IFTTT